PA
RLMD icon

Parallel Advisors’s Relmada Therapeutics RLMD Stock Holding History

Parallel Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-582
Closed -$1.31K – 3494
2023
Q1 		$1.31K Sell
582
-122
-17% -$421 ﹤0.01% 2893
2022
Q4 		$2.46K Buy
704
+700
+17,500% +$6.15K ﹤0.01% 2606
2022
Q3 		$0 Buy
+4
New +$111 ﹤0.01% 3435
2021
Q4 		– Sell
-184
Closed -$5K – 3260
2021
Q3 		$5K Buy
+184
New +$4.92K ﹤0.01% 2382

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Parallel Advisors's RLMD Position: Q2 2023 in Review

Parallel Advisors sold out of Relmada Therapeutics (RLMD) in Q2 2023, closing a stake of 582 shares — an estimated $1.31K sold.

Parallel Advisors first reported a position in RLMD in Q3 2021 and held it in 4 quarters. The position peaked at $5K in Q3 2021. 95 funds tracked by Wall St. Rank hold RLMD as of Q2 2023.

  • Parallel Advisors reported no remaining Relmada Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Parallel Advisors sold 582 Relmada Therapeutics shares in Q2 2023, an estimated $1.31K.
  • Parallel Advisors first reported a position in Relmada Therapeutics in Q3 2021 and held it in 4 quarters.
  • Parallel Advisors's Relmada Therapeutics position peaked at $5K in Q3 2021.
  • 95 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2023.

Based on Parallel Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.